Nutriband (NTRB) AI Stock Analysis

• Market Cap: $53.20M
• Dividend Yield: N/A
• Average Volume (3M): 31.62K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.56
• Revenue Growth: 12.69%
• EPS Growth: -329.78%
• Country: US
• Employees: 13
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.98
• Shares Outstanding: 12,174,883
• 10 Day Avg. Volume: 33,995
• 30 Day Avg. Volume: 31,617
• PEG Ratio: -0.19
• Price to Book (P/B): 13.68
• Price to Sales (P/S): 41.09
• P/FCF Ratio: -18.63
• Enterprise Value/Market Cap: 1.13
• Enterprise Value/Revenue: 26.31
• Enterprise Value/Gross Profit: 80.61
• Enterprise Value/Ebitda: -4.76
• 1Y Price Target: $15.00
• Price Target Upside: 239.37% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 53 Neutral
• Price Target: $7.50 ▲(69.68% Upside)

Nutriband's overall stock score is driven by a strong corporate event with positive market reception, offset by challenging financial performance and valuation issues. The technical analysis provides mixed signals, suggesting cautious optimism. The potential for shareholder value enhancement through recent corporate actions improves the score despite underlying financial weaknesses.

Positive Factors

Business Model Strength

Nutriband's focus on transdermal drug delivery systems offers a unique value proposition in healthcare, enhancing patient compliance and therapeutic outcomes.

Strategic Collaborations

Partnerships with pharmaceutical companies for co-development and licensing agreements expand market access and support revenue growth.

Shareholder Value Enhancement

Issuing Series A Preferred Stock positions Nutriband favorably in the market, potentially increasing shareholder value and financial stability.

Negative Factors

Profitability Challenges

Ongoing operational losses and negative cash flows indicate difficulty in achieving profitability, impacting long-term business sustainability.

Negative Cash Flow

Reliance on financing to offset cash deficits is unsustainable, posing risks to financial health if operational improvements are not realized.

Volatile Profit Margins

Inconsistent profit margins highlight challenges in cost management, affecting long-term profitability and competitive positioning.

Nutriband Business Overview & Revenue Model

Company Description

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

How the Company Makes Money

Nutriband generates revenue through the commercialization of its transdermal patch products. The company primarily earns money by selling its patches directly to healthcare providers and distributors, as well as through partnerships with pharmaceutical companies for co-development and licensing agreements. Additionally, Nutriband may benefit from royalties on sales of products developed utilizing its technology. Strategic collaborations with industry players enhance its market reach and provide additional financial backing, contributing to the overall revenue model.

Nutriband Financial Statement Overview

Summary

Nutriband faces significant challenges in improving profitability and cash flow. While there is some revenue growth, persistent losses and negative cash flows are critical issues. The balance sheet is stable due to low leverage, but ongoing losses and reliance on external financing could pose risks.

Income Statement

Nutriband has shown modest revenue growth over the years, but profitability remains a challenge with consistently negative EBIT and net income margins. Revenue increased by 2.6% from 2024 to 2025, indicating slow growth. However, the gross profit margin has been volatile, and the net profit margin remains deeply negative, reflecting the company's difficulty in managing costs in relation to revenues.

Balance Sheet

The balance sheet is relatively stable, with a low debt-to-equity ratio indicating conservative leverage. Stockholders' equity remains strong at approximately 86% of total assets. However, the company's return on equity is negative due to ongoing net losses, which could be concerning for long-term sustainability.

Cash Flow

Nutriband's cash flow situation is challenging, with negative operating and free cash flows reflecting ongoing operational losses. The operating cash flow to net income ratio is negative, indicating cash outflows exceed net losses. The company relies heavily on financing cash flows to offset operating cash deficits, which is not sustainable long-term.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.28M	2.14M	2.09M	2.08M	1.42M	943.70K
Gross Profit	743.53K	699.30K	862.11K	750.41K	504.31K	361.32K
EBITDA	-12.59M	-10.18M	-5.12M	-4.11M	-5.74M	-2.48M
Net Income	-12.78M	-10.48M	-5.49M	-4.81M	-8.42M	-3.21M
Balance Sheet
Total Assets	8.42M	7.47M	7.52M	9.46M	12.74M	9.93M
Cash, Cash Equivalents and Short-Term Investments	5.31M	4.31M	492.94K	1.99M	4.89M	151.99K
Total Debt	216.42K	186.35K	241.28K	185.81K	134.57K	1.79M
Total Liabilities	870.21K	1.04M	1.08M	883.39K	880.38K	2.82M
Stockholders Equity	7.55M	6.43M	6.44M	8.57M	11.86M	7.11M
Cash Flow
Free Cash Flow	-5.64M	-4.72M	-3.58M	-3.07M	-2.89M	-297.06K
Operating Cash Flow	-5.64M	-4.63M	-3.53M	-2.99M	-2.81M	-297.06K
Investing Cash Flow	-5.32K	-92.04K	-51.76K	-79.30K	-81.59K	66.99K
Financing Cash Flow	5.26M	8.54M	2.09M	160.07K	7.63M	371.87K

Nutriband Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.42
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NTRB, the sentiment is Negative. The current price of 4.42 is below the 20-day moving average (MA) of 4.52, below the 50-day MA of 4.91, and below the 200-day MA of 6.39, indicating a bearish trend. The MACD of -0.20 indicates Negative momentum. The RSI at 43.46 is Neutral, neither overbought nor oversold. The STOCH value of 25.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NTRB.

Nutriband Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CSBR	55 Neutral	$99.60M	43.33	102.74%	―	9.06%	―
NTRB	53 Neutral	$53.20M	-1.42	-98.00%	―	12.69%	-329.78%
ADAG	52 Neutral	$90.49M	-3.04	-63.41%	―	-87.59%	11.53%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ALXO	48 Neutral	$65.60M	-0.58	-118.95%	―	―	31.98%
IFRX	43 Neutral	$67.13M	-0.95	―	―	―	―
PLRX	42 Neutral	$78.66M	-0.45	-64.27%	―	―	14.19%

Nutriband Corporate Events

Nutriband Divests Pocono Stake to Fund AVERSA Fentanyl

On December 29, 2025, Nutriband Inc. announced that it has signed an agreement to sell a 90% stake in its subsidiary Pocono Pharmaceutical to EarthVision Bio for $5 million, with closing expected on December 31, 2025. Following the transaction, Nutriband shareholders will retain a 10% shareholding in EarthVision Bio, which is commercializing a new category of sustainable alternatives to plastic, molded fiber, wood and paper products developed by Intel founder Dr. Gordon Moore and former Chevron Europe chairman Dr. Hans Franke. Nutriband plans to use the sale proceeds to advance development of AVERSA Fentanyl, which it positions as a potential first-in-class abuse-deterrent opioid patch with an estimated U.S. annual sales opportunity of $80 million to $200 million, signaling a strategic capital redeployment toward its core transdermal drug-delivery platform and lead product candidate.

The most recent analyst rating on (NTRB) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Nutriband stock, see the NTRB Stock Forecast page.

Nutriband Advances with FDA on Fentanyl Patch

Nutriband Inc. announced the successful completion of a meeting with the US FDA regarding its AVERSA™ FENTANYL patch, an abuse-deterrent transdermal system. The meeting, held on September 18, 2025, provided Nutriband with feedback on its Chemistry, Manufacturing, and Controls plans, which will be integrated into their development program as they move towards an IND filing. The FDA’s guidance is crucial as Nutriband aims to address the significant issue of fentanyl patch abuse and potentially become the first to market an abuse-deterrent fentanyl patch globally. The collaboration with Kindeva and the potential market impact, with projected US sales reaching $80 million to $200 million annually, underscore the strategic importance of this development.

The most recent analyst rating on (NTRB) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Nutriband stock, see the NTRB Stock Forecast page.